Kidney disease diagnostics company Renalytix plc (LSE:RENX) reported an operating loss of US$14.0m for the twelve months to 30 June 2026, down from US$17.2m, on flat revenue of US$3.0m. After the period it signed a US national distribution agreement with Quest Diagnostics and raised about US$14m in a placing.

What was announced

On 28 October 2026, Renalytix plc, listed in London as RENX, published unaudited results for the twelve months to 30 June 2026. The figures have been prepared under IAS 34 and are not statutory accounts. Renalytix is moving its accounting reference date to 31 December 2026, as announced on 14 September 2026. As a result, its next audited results will cover the 18 months to 31 December 2026 and are due by 30 June 2027.

The company's main product is kidneyintelX.dkd, a test designed to assess the risk of progressive kidney disease in patients with type 2 diabetes. Chief executive James McCullough said: "Cost discipline has become embedded across all aspects of the organization."

The numbers

Total revenue was US$3.0m, unchanged from the prior year. Within that, commercial test revenue fell to US$2.2m from US$2.7m, and life sciences revenue rose to US$0.8m from US$0.3m. Gross profit was US$1.2m in both periods.

Administrative expenses fell by US$3.2m to US$15.2m from US$18.4m. As a result, the operating loss narrowed to US$14.0m from US$17.2m. The underlying EBITDA loss was US$12.1m, compared with US$14.0m. The loss for the period was US$14.2m, against US$20.4m. The weighted average number of shares rose to about 410 million from about 275 million, and the basic and diluted loss per share was US$0.03, compared with US$0.07.

Cash at 30 June 2026 was US$1.4m, down from US$3.6m, after an operating cash outflow of US$10.9m. At the balance sheet date, total liabilities of US$10.9m exceeded total assets of US$4.6m, leaving a net liabilities position of US$6.3m.

Quest agreement and financing

In September 2026, after the period end, Renalytix (LSE:RENX) signed a multi-year US national distribution agreement with Quest Diagnostics. Under the agreement, patients can have blood drawn at Quest's roughly 2,000 patient service centres or by its in-office phlebotomists. The samples are then sent to Renalytix's New York laboratory for testing. Mr McCullough said kidneyintelX.dkd "will be deployed directly to approximately 50% of all US physicians who currently use Quest services".

The company plans a US national launch beginning in the first quarter of 2027. It expects testing growth to accelerate into the second half of 2027 and beyond, and is targeting capacity for 200,000 tests a year in 2028. Its new Long Island City laboratory is expected to provide more than three times the previous capacity, at about one-third of the facility cost.

Also in September 2026, Renalytix raised about US$14m gross through an over-subscribed institutional placing. About US$4.6m of debt was converted into new shares, and the company said no convertible debt remains outstanding.

Going concern and what to watch next

The directors expect existing cash resources to provide about twelve months of runway from the date of the report. They disclosed a material uncertainty that "may cast significant doubt" on the company's ability to continue as a going concern, and said further funding may be needed to reach cash-flow breakeven.

During the year, Renalytix onboarded more than 233 new physicians and increased the number of fully integrated practices to ten from two. It also reported payment on more than 95% of submitted Medicare and Medicare Advantage claims. The company has also applied for CE marking in Europe.

The main things to watch are the start of the Quest national launch, test volumes in 2027 and any further funding. The audited results for the 18 months to 31 December 2026 are due by 30 June 2027.